These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6280337)

  • 41. Both DR and MT class II HLA molecules may restrict proliferative T-lymphocyte responses to antigen.
    Berle EJ; Thorsby E
    Scand J Immunol; 1982 Dec; 16(6):543-7. PubMed ID: 6186016
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunity to herpes simplex virus in children receiving treatment for acute lymphoblastic leukaemia (ALL).
    Tellez PA; Odom L; Hayward AR
    Clin Exp Immunol; 1985 Dec; 62(3):525-9. PubMed ID: 3002690
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Humoral and cell-mediated immunity in herpes simplex virus infection].
    Eis-Hübinger AM; Schneweis KE
    Monatsschr Kinderheilkd; 1991 Jul; 139(7):391-5. PubMed ID: 1656247
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Detection of antigen and antibody in herpes simplex encephalitis].
    Smetana Z; Leventon-Kriss S; Gotlieb-Stematsky T
    Harefuah; 1989 Nov; 117(9):233-5. PubMed ID: 2559006
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune responses to herpes simplex virus in patients with recurrent herpes labialis: I. Development of cell-mediated cytotoxic responses.
    Tsutsumi H; Bernstein JM; Riepenhoff-Talty M; Cohen E; Orsini F; Ogra PL
    Clin Exp Immunol; 1986 Dec; 66(3):507-15. PubMed ID: 2436840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Viral isolation and systemic immune responses after intracameral inoculation of herpes simplex virus type 1 in Igh-1-disparate congenic murine strains.
    Hemady R; Tauber J; Ihley TM; Opremcak EM; Foster CS
    Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2335-41. PubMed ID: 2173686
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD.
    Zarling JM; Moran PA; Burke RL; Pachl C; Berman PW; Lasky LA
    J Immunol; 1986 Jun; 136(12):4669-73. PubMed ID: 2423598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autologous herpes simplex virus-infected cells are lysed by human natural killer cells.
    Yasukawa M; Zarling JM
    J Immunol; 1983 Oct; 131(4):2011-6. PubMed ID: 6311903
    [No Abstract]   [Full Text] [Related]  

  • 49. Cell-mediated immunity to herpes simplex virus types 1 and 2 antigens in leukoplakia and carcinoma in man.
    Shillitoe EJ; Tarro G; Lehner T
    Oncology; 1976; 33(4):192-5. PubMed ID: 65753
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Virus antibodies in Parkinson's disease. Herpes simplex and measles virus antibodies in serum and CSF and their relation to HLA types.
    Marttila RJ; Rinne UK; Tiilikainen A
    J Neurol Sci; 1982 May; 54(2):227-38. PubMed ID: 6284883
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Herpes simplex virus type-2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans.
    Mertz GJ; Peterman G; Ashley R; Jourden JL; Salter D; Morrison L; McLean A; Corey L
    J Infect Dis; 1984 Aug; 150(2):242-9. PubMed ID: 6088648
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The quest for a herpes simplex virus vaccine: background and recent developments.
    Hall MJ; Katrak K
    Vaccine; 1986 Sep; 4(3):138-50. PubMed ID: 3020819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role for major histocompatibility complex class I in regulating natural killer cell-mediated killing of virus-infected cells.
    Kaufman DS; Schoon RA; Leibson PJ
    Proc Natl Acad Sci U S A; 1992 Sep; 89(17):8337-41. PubMed ID: 1325654
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Native HSV glycoprotein D subunit vaccine: analysis of in vitro T-cell activation and antigen presentation.
    Ishizaka ST; Mishkin EM
    Viral Immunol; 1991; 4(3):187-93. PubMed ID: 1667262
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Humoral and cell-mediated immunity in neonates with herpes simplex virus infection.
    Sullender WM; Miller JL; Yasukawa LL; Bradley JS; Black SB; Yeager AS; Arvin AM
    J Infect Dis; 1987 Jan; 155(1):28-37. PubMed ID: 3025306
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Marrow donor immunity to herpes simplex virus: association with acute graft-versus-host disease.
    Gratama JW; Sinnige LG; Weijers TF; Zwaan FE; van Heugten JG; Stijnen T; D'Amaro J; The TH; Hekker AC; de Gast GC
    Exp Hematol; 1987 Aug; 15(7):735-40. PubMed ID: 3038583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
    Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
    Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reactivation of herpes simplex virus is associated with production of a low molecular weight factor that inhibits lymphokine activity in vitro.
    Sheridan JF; Beck M; Smith CC; Aurelian L
    J Immunol; 1987 Feb; 138(4):1234-9. PubMed ID: 3027176
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Studies on human epidermal Langerhans' cells: II. Activation of human T lymphocytes to herpes simplex virus.
    Braathen LR; Berle E; Mobech-Hanssen U; Thorsby E
    Acta Derm Venereol; 1980; 60(5):381-7. PubMed ID: 6162307
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cellular interactions in the cytotoxic T lymphocyte response to herpes simplex virus antigens: differential antigen activation requirements for the helper T lymphocyte and cytotoxic T lymphocyte precursors.
    Schmid DS; Rouse BT
    J Immunol; 1983 Jul; 131(1):479-84. PubMed ID: 6223080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.